NO20010918L - Ekspresjon og eksport av angiostatin og endostatin som immunofusiner - Google Patents

Ekspresjon og eksport av angiostatin og endostatin som immunofusiner

Info

Publication number
NO20010918L
NO20010918L NO20010918A NO20010918A NO20010918L NO 20010918 L NO20010918 L NO 20010918L NO 20010918 A NO20010918 A NO 20010918A NO 20010918 A NO20010918 A NO 20010918A NO 20010918 L NO20010918 L NO 20010918L
Authority
NO
Norway
Prior art keywords
region
endostatin
immunofusins
angiostatin
export
Prior art date
Application number
NO20010918A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010918D0 (no
Inventor
Kin-Ming Lo
Yue Li
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20010918D0 publication Critical patent/NO20010918D0/no
Publication of NO20010918L publication Critical patent/NO20010918L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20010918A 1998-08-25 2001-02-23 Ekspresjon og eksport av angiostatin og endostatin som immunofusiner NO20010918L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9788398P 1998-08-25 1998-08-25
PCT/US1999/019329 WO2000011033A2 (en) 1998-08-25 1999-08-25 Expression and export of angiostatin and endostatin as immunofusins

Publications (2)

Publication Number Publication Date
NO20010918D0 NO20010918D0 (no) 2001-02-23
NO20010918L true NO20010918L (no) 2001-04-19

Family

ID=22265602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010918A NO20010918L (no) 1998-08-25 2001-02-23 Ekspresjon og eksport av angiostatin og endostatin som immunofusiner

Country Status (20)

Country Link
US (3) US20030139365A1 (enExample)
EP (1) EP1107989B1 (enExample)
JP (3) JP2002523036A (enExample)
CN (2) CN100422332C (enExample)
AT (1) ATE462725T1 (enExample)
AU (1) AU761027B2 (enExample)
BR (1) BR9913331A (enExample)
CA (1) CA2339331C (enExample)
CZ (1) CZ302303B6 (enExample)
DE (1) DE69942207D1 (enExample)
DK (1) DK1107989T3 (enExample)
ES (1) ES2342239T3 (enExample)
HK (1) HK1042503A1 (enExample)
HU (1) HUP0103329A3 (enExample)
NO (1) NO20010918L (enExample)
PL (1) PL202057B1 (enExample)
PT (1) PT1107989E (enExample)
RU (1) RU2240328C2 (enExample)
WO (1) WO2000011033A2 (enExample)
ZA (1) ZA200101290B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1705248A1 (en) * 1997-10-01 2006-09-27 G.D. Searle LLC. Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1071468B1 (en) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
ES2342239T3 (es) * 1998-08-25 2010-07-02 Merck Patent Gmbh Expresion y exportacion de angiostatina y de endostatina como inmunofusinas.
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60025832T2 (de) 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
IL131803A0 (en) * 1999-09-08 2001-03-19 Genena Ltd Method for improving the efficiency of cancer gene therapy
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
JP2003000268A (ja) * 2000-08-25 2003-01-07 Pfizer Prod Inc 血管新生にかかわる疾患を診断および治療するための方法および組成物
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US7160858B2 (en) 2000-09-01 2007-01-09 Philadelphia, Health And Education Corporation Methods and compositions for inhibiting angiogenesis
AU2001288648A1 (en) * 2000-09-01 2002-03-13 Philadelphia, Health And Education Corporation Methods and compositions for inhibiting angiogenesis
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US7893033B2 (en) 2002-05-06 2011-02-22 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
JP2007529410A (ja) * 2003-08-29 2007-10-25 チルドレンズ メディカル センター コーポレーション 子宮内膜症を治療又は防止するためのペプチド
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
JP2005301419A (ja) * 2004-04-07 2005-10-27 Hitachi Ltd ディスクアレイ装置およびそのデータ処理方法
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
RU2303997C2 (ru) * 2005-09-27 2007-08-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Конъюгат, обладающий избирательным действием по отношению к раковым опухолям
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CN101292036B (zh) * 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 用于重组表达多肽的方法
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
AT506216B1 (de) 2008-02-13 2009-07-15 Peter Dr Hernuss Zusammensetzung zur aufnahme über mukoses gewebe
RU2372354C1 (ru) * 2008-02-28 2009-11-10 Сергей Викторович Луценко Слитый белок, имеющий активность ингибитора ангиогенеза
JP2012521784A (ja) * 2009-03-30 2012-09-20 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー イヌＦｃ部分を含む融合タンパク質
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
KR101579318B1 (ko) * 2010-04-29 2015-12-21 엘지전자 주식회사 태양 전지 및 그 제조 방법
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
RU2465283C1 (ru) * 2011-06-27 2012-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвити Рекомбинантный гибридный полипептид, способный ингибировать пролиферацию эндотелиальных клеток человека in vitro, и способ его получения
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
WO2014200312A1 (ko) * 2013-06-14 2014-12-18 주식회사 엘지화학 유기태양전지 및 이의 제조방법
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160126391A1 (en) * 2014-10-31 2016-05-05 Byd Company Limited Solar cell module and manufacturing method thereof
AU2016341402B2 (en) * 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
CN108368511B (zh) * 2015-10-23 2022-12-06 阿珀吉科吉尼科斯股份公司 单链cd137受体激动剂蛋白
EP3383424A1 (en) 2015-12-03 2018-10-10 Deutsches Krebsforschungszentrum Means and methods for treating and diagnosing fibrosis or fibrosis-associated diseases
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109824779B (zh) * 2017-11-23 2023-05-26 中山大学 一种包含IgG的Fc结构域和EB病毒包膜糖蛋白胞外域的融合蛋白
US11845784B2 (en) 2018-04-17 2023-12-19 Heidelberg Biotech Gmbh Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising NC-1-Fc
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
US20240100134A1 (en) * 2021-01-20 2024-03-28 Monash University Fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5643783A (en) * 1993-12-01 1997-07-01 President And Fellows Of Harvard College Collagen and uses therefor
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
ES2206602T3 (es) * 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1071468B1 (en) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
MXPA00010151A (es) * 1998-04-17 2002-08-06 Lexigen Pharm Corp Mejoramiento de las respuestas inmunes mediadas por proteina de fusion de anticuerpo-citocina mediante la soadministracion con inhibidores de prostaglandina.
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
ES2342239T3 (es) * 1998-08-25 2010-07-02 Merck Patent Gmbh Expresion y exportacion de angiostatina y de endostatina como inmunofusinas.
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin

Also Published As

Publication number Publication date
CN100422332C (zh) 2008-10-01
NO20010918D0 (no) 2001-02-23
PL202057B1 (pl) 2009-05-29
WO2000011033A2 (en) 2000-03-02
HUP0103329A2 (hu) 2001-12-28
JP2009273478A (ja) 2009-11-26
US20130165634A1 (en) 2013-06-27
CN1326467A (zh) 2001-12-12
CA2339331A1 (en) 2000-03-02
EP1107989A2 (en) 2001-06-20
US8206718B2 (en) 2012-06-26
ZA200101290B (en) 2002-02-15
US8703908B2 (en) 2014-04-22
JP2002523036A (ja) 2002-07-30
JP2013128490A (ja) 2013-07-04
HUP0103329A3 (en) 2003-09-29
WO2000011033A3 (en) 2000-06-22
US20070009538A1 (en) 2007-01-11
ES2342239T3 (es) 2010-07-02
DK1107989T3 (da) 2010-05-25
BR9913331A (pt) 2001-05-15
CZ302303B6 (cs) 2011-02-16
CA2339331C (en) 2011-03-01
CZ2001643A3 (cs) 2002-02-13
PT1107989E (pt) 2010-07-02
CN101386651A (zh) 2009-03-18
AU5583699A (en) 2000-03-14
AU761027B2 (en) 2003-05-29
RU2240328C2 (ru) 2004-11-20
PL346703A1 (en) 2002-02-25
ATE462725T1 (de) 2010-04-15
DE69942207D1 (de) 2010-05-12
US20030139365A1 (en) 2003-07-24
EP1107989B1 (en) 2010-03-31
HK1042503A1 (zh) 2002-08-16

Similar Documents

Publication Publication Date Title
NO20010918D0 (no) Ekspresjon og eksport av angiostatin og endostatin som immunofusiner
DE69533675D1 (de) Monoklonaler antikörper gegen rhesus d (d7c2)
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
TR199902878T2 (xx) Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
EA199900162A1 (ru) Ингибиторы клеточной адгезии
EA200300382A1 (ru) Способ поэтапного присоединения частей полиэтиленгликоля к полипептиду
NO996276D0 (no) Forbedret prosess for kondensering av naturgass
BR9810654B8 (pt) mÉtodo de preparaÇço de um polipeptÍdeo, molÉculas de anticorpo e composiÇço.
NO2013009I1 (no) Alipogen tiparvovec
EA200100216A1 (ru) Композиции на основе слитого белка ов и способы их применения
ID30327A (id) EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc
BG102577A (bg) Нови 5-амино-3-циано-4-етилсулфинил-1-фенилпиразоли, метод за получаване и използването им като пестициди
DE59705574D1 (de) Biologisch abbaubare zusammensetzung
WO2001034646A3 (en) Recombinant gelatins
AU2152299A (en) Multivalent antigen-binding proteins
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
TR199901695T2 (xx) Havu� antifriz polipeptidleri.
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
ATE285474T1 (de) Haemophilus adhäsionsproteinen
DK0809695T3 (da) Transkriptionsfaktor E2F-5
NL1003768A1 (nl) Elektrodeloze gasontladingslamp.
EP0804556A4 (en) PROTEIN MODIFYING ENZYME
DK0829579T3 (da) Farbart bindelag og fremgangsmåde til den fremstilling
NL1000537A1 (nl) Gasontladingsluitschakelaar.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application